Traditional mammography takes two images of each breast, a side-to-side and top-to-bottom view. Freeman said this technology provides a beneficial service for patients who may have denser breast ...

NEW YORK – Immuneering on Thursday said it signed a clinical supply agreement with Regeneron to obtain the anti-PD-1 therapy Libtayo (cemiplimab ... of the trial reported last year, among 22 patients ...

“We remain focused on our shared priority with Regeneron - ensuring we continue to support the community of patients and caregivers who rely ... including the cancer therapy Libtayo and the ...

in combination with Regeneron's anti-PD-1 therapy, Libtayo (cemiplimab). The company's stock has shown remarkable resilience, posting a 54% gain over the past six months, according to InvestingPro ...

Regeneron is a global leader in cancer research and development, and the combination of IMM-1-104 and Libtayo in advanced non-small cell lung cancer has the potential to address unmet needs for ...

The supply agreement supports the evaluation of Immuneerings' lead product candidate, IMM-1-104, in combination with Regeneron's immunotherapy drug Libtayo in patients with advanced non-small cell ...

The supply agreement supports the evaluation of Immuneering’s lead product candidate, IMM-1-104, in combination with Libtayo in patients with ... with IMM-1-104. Regeneron is a global leader ...